iNKT cell infusion for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new type of immune cell therapy called iNKT cells for people with advanced pancreatic cancer that has not responded to standard treatments. The cells are from a healthy donor and may help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer that cannot be removed by surgery and has not responded to at least one standard treatment.
- You are between 18 and 75 years old.
- You have at least one tumor that can be measured on scans.
- You are in reasonably good health with an ECOG performance status of 0 or 1 (able to carry out daily activities).
- You have not had other cancer treatments, such as chemotherapy, within the past 30 days.
- You do not have serious heart, lung, autoimmune, or active infection problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.
This trial tests a new type of immunotherapy called CAR-NK cells (CL-NK-001) for patients with advanced pancreatic cancer that has a specific marker (eGR1). The goal is to see if these specially grown natural killer cells can attack the cancer after standard treatments have stopped working.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
This Phase 1/2 trial tests a new medicine (IN10018) and a specific added antibody (KN046) together with standard chemotherapy for advanced pancreatic cancer. It aims to see whether this combination can better control the cancer and how safely it can be given.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.